EMEA-002700-PIP01-19

Table of contents

Key facts

Active substance
Crinecerfont
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0104/2021
PIP number
EMEA-002700-PIP01-19
Pharmaceutical form(s)
  • Capsule, hard
  • Oral solution
Condition(s) / indication(s)
Treatment of congenital adrenal hyperplasia
Route(s) of administration
  • Oral use
  • Gastric use
Contact for public enquiries
Neurocrine Therapeutics Ltd

E-mail: medinfo@neurocrine.com
Tel. +01 8776 413461

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating